Alder Biopharmaceuticals
ALDR
ALDR was delisted on the 21st of October, 2019.
124 hedge funds and large institutions have $733M invested in Alder Biopharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 39 increasing their positions, 36 reducing their positions, and 21 closing their positions.
8% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 36
2% less funds holding
Funds holding: 127 → 124 (-3)
14% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 21
38% less capital invested
Capital invested by funds: $1.19B → $733M (-$454M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
62% less call options, than puts
Call options by funds: $253K | Put options by funds: $673K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$20.1M |
| 2 |
SC
Samlyn Capital
New York
|
+$11.6M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$8M |
| 4 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$6.4M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$6.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$31.9M |
| 2 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$16.7M |
| 3 |
Man Group
London,
United Kingdom
|
-$8.55M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$6.16M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.07M |
ALDR Hedge Fund Activity: Q4 2018 in Review
124 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Alder Biopharmaceuticals (ALDR) for Q4 2018, worth a combined $733M — down 38% from $1.19B a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of ALDR and 18 opened new positions — a net loss of 3 holders — while 36 trimmed existing stakes and 39 added.
The largest buyer was Goldman Sachs, adding an estimated $20.1M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $31.9M sold.
- 124 institutional investors held Alder Biopharmaceuticals (ALDR) as of Q4 2018, down from 127 in Q3 2018.
- Funds reported $733M of Alder Biopharmaceuticals stock for Q4 2018, down 38% quarter-over-quarter.
- 18 funds opened new Alder Biopharmaceuticals positions in Q4 2018 and 21 closed out, a net change of -3 holders.
- The largest Alder Biopharmaceuticals buyer in Q4 2018 was Goldman Sachs, an estimated $20.1M added.
- The largest Alder Biopharmaceuticals seller in Q4 2018 was PFM Health Sciences, an estimated $31.9M sold.
Based on aggregated 13F filings for Q4 2018.